Neogenomics, Inc. (NASDAQ: NEO) has recently appointed Dr. Marjorie Green to its board of directors, effective June 19, 2025. Dr. Green, who is currently the Senior Vice President and Head of Oncology, Global Clinical Development at Merck, brings with her a wealth of experience in the life sciences industry, particularly in clinical oncology, corporate strategy, and business development.
Before joining Merck, Dr. Green held positions at Seagen and Genentech, where she oversaw late-stage development and led the breast and gynecologic cancer franchise, respectively. Her extensive career also includes roles at MD Anderson Cancer Center, where she served as a medical oncologist and later as the medical director of the Nellie B. Connally Breast Center.
Dr. Green's educational background includes a BA in history from the University of Notre Dame, an MD from the University of Texas Medical Branch, and residencies and fellowships at the University of Virginia School of Medicine and the University of Texas MD Anderson Cancer Center.
With this appointment, Neogenomics aims to leverage Dr. Green's expertise to accelerate innovation in the precision oncology market. Lynn Tetrault, the Chair of the Board of Neogenomics, expressed enthusiasm about Dr. Green's appointment, highlighting her deep expertise in clinical oncology and pipeline development.
Neogenomics, Inc. is a premier cancer diagnostics company that specializes in cancer genetics testing and information services. Headquartered in Fort Myers, FL, the company operates a network of CAP-accredited and CLIA-certified laboratories across the US, as well as a full-service sample-processing laboratory in Cambridge, United Kingdom. Neogenomics provides comprehensive oncology-focused testing menus to serve oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms.
Dr. Green expressed her honor in joining Neogenomics' board at a pivotal time for the company, emphasizing the company's unique oncology diagnostics offerings and its potential for growth. Her appointment reflects Neogenomics' commitment to improving patient care and advancing its mission in the field of precision oncology. The market has reacted to these announcements by moving the company's shares 2.85% to a price of $7.21. For the full picture, make sure to review NEOGENOMICS INC's 8-K report.
